Analytical Data
-
基因名
ERGIC2
- Application
-
别名
ERGIC2; ERV41; PTX1; CDA14; Endoplasmic reticulum-Golgi intermediate compartment protein 2
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q96RQ1
-
表达区间
1-215aa
-
氨基酸序列
MRRLNRKKTLSLVKELDAFPKVPESYVETSASGGTVSLIAFTTMALLTIMEFSVYQDTWMKYEYEVDKDFSSKLRINIDITVAMKCQYVGADVLDLAETMFASADGLVYEPTVFDLSPQQKEWQRMLQLIQSRLQEEHSLQDVIFKSAFKSTSTALPPREDDSSQSPNACRIHGHLYVNKVAGNFHITVGQFHILVVMHIWQHLSTMNLTIFLIE
-
分子量
51 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ERGIC2, or ER-Golgi intermediate compartment protein 2, is an essential component of the secretory pathway, particularly involved in the transport between the endoplasmic reticulum (ER) and the Golgi apparatus. The study of ERGIC2 has gained traction due to its significant role in protein sorting and trafficking, which are critical processes for maintaining cellular homeostasis and function. Dysregulation of these processes can contribute to various diseases, including neurodegenerative disorders and certain types of cancer. Recent research has focused on understanding the molecular mechanisms underlying ERGIC2's function and its interactions with other cellular components, such as coat protein complexes and molecular chaperones. These investigations utilize advanced techniques, including cryo-electron tomography and live-cell imaging, to visualize ERGIC2 dynamics within the cellular context. Additionally, studies have explored the potential of ERGIC2 as a biomarker for specific pathologies and its implications in therapeutic strategies aimed at restoring normal cellular transport mechanisms. The ongoing exploration of ERGIC2 not only enhances our understanding of the fundamental aspects of intracellular trafficking but also positions this protein as a potential target for drug development in diseases linked to protein misfolding and transport defects.
